← All trials
NCT04350580
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Jun 30, 2020
- Completion date
- Aug 31, 2020
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 138
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre Hospitalier St AnneLead sponsor
- Laboratoire français de Fractionnement et de BiotechnologiesCollaborator
- Centre Hospitalier St AnneStudy chair
- Centre Hospitalier St AnneOverall official - principal investigator
- Groupe Hospitalier Universitaire Paris psychiatrie & neurosciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.